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Exhaled nitric oxide (eNO) is indicative of the
severity of the airway inflammation in asthma.1,2
Consequently, this non-invasive, patient-friendly
methodology has recently been introduced into
clinical practice as a diagnostic and monitoring tool
especially for children.3–5 However, despite stan-
dardization of the eNO protocol,6 there are still
some issues that need to be addressed. For
example, whether there does or does not exist a
relationship between the airway calibre and the
eNO levels. A clear-cut relationship of eNO and the
airway calibre may have implications for the
measurements.7–10Elsevier Ltd. All rights reserv
+31 71 5246466; fax:
emon.nl (Z. Diamant).Late asthmatic airway response (LAR) to inhaled
allergen, defined as a fall in forced expiratory
volume in 1 s (FEV1) of at least 15% from pre-
allergen baseline,11 has been shown to be asso-
ciated with airway inflammation, including in-
creased levels of eNO.12 We hypothesized that
eNO levels during LAR are related to the degree of
airway narrowing. Therefore, we studied the effect
of vigorous bronchodilation with inhaled salbuta-
mol during LAR on eNO levels.Subjects and methods
Subjects
Data from 12 asthmatics (6M/6F, 21–40 y) PC20FEV1
methacholineo8mg/mL) with mild to moderate
persistent asthma (FEV1 73.6–121.4% pred.) anded.
ARTICLE IN PRESS
J.D. Boot et al.1592dual responses to inhaled house-dust mite (HDM)
extract participating in an intervention study were
used. All subjects had a history of persistent
asthma for at least 1 year (according to criteria
by GINA 2002), without any other clinically relevant
disorders. None of the subjects had smoked
tobacco during the past year. None was using
concomitant anti-asthma or anti-allergy medica-
tion for at least 6 weeks prior to and during the
study, except for inhaled short-acting b2-agonists
prn. There was no history of viral infections of the
lower airways for at least 4 weeks. The study was
approved by the Ethics Committee of the Leiden
University Medical Center and all participants gave
written consent.
Study design
The allergen-induced airway response during the
LAR was measured at 1-h intervals until 9-h post-
allergen. To reverse the LAR, 600 mg salbutamol was
administered through an aerochamber (Volu-
matics), and the FEV1 was repeated 15min later.
Exhaled NO was measured before and approxi-
mately 30min post-salbutamol. For ethical reasons,
no placebo-arm was included in this study.Methods
Allergen bronchoprovocation test
The allergen bronchoprovocation test was per-
formed using the standardized 2-min tidal breath-
ing method according to Cockcroft et al.11 Purified
aqueous allergen extract of Dermatophagoides
Pterinyssinus (SQ503, ALK-BPT, ALK-Abello´, Nieu-
wegein, The Netherlands), with 0.5% phenol as a
preservative was used for the bronchoprovocation
tests (BPT). Preparation of the HDM extract
dilutions was performed according a previously
validated protocol.13 The allergen aerosols were
generated by a DeVilbiss 646 nebulizer (output
0.13mL/min) connected to an in-and expiratory
valve box with an expiratory aerosol filter (Pall
Ultipor BB50 T, Medica BV, Den Bosch, The Nether-
lands). Subjects first inhaled the allergen diluent,
and provided the subsequent fall in FEV1 remained
o10% of baseline, they subsequently inhaled a
total of three doubling concentrations of HDM
extract at 12min intervals that have previously
caused a LAR The airway response during the LAR
was measured at 1-h intervals until 9 h post-
allergen or earlier if subjects experienced unbear-
able discomfort or the FEV1 fell below 1.4 L.Airway response
The airway response to the inhaled aerosols was
measured by FEV1 according to standardized lung
function techniques14 and recorded by a spirometer
connected to a PC (Vmax Spectra, Sensor Medics,
Bilthoven, The Netherlands). At each specified
timepoint, the FEV1 was measured in duplicate,
and the highest, technically satisfactory FEV1 was
implicated in the analysis. The airway response was
quantified as percentage change from pre-allergen
baseline FEV1.
Exhaled NO measurements
Exhaled NO levels were measured in triplicate
(within 10%) by a chemoluminescence analyzer
(Ecomedics CLD88sp, Duernten, Switzerland) at
the specified timepoints. The mean ppb-value was
implicated in the analysis; the response was
quantified as percentage change from pre- to
post-salbutamol value.
Analysis
FEV1 and eNO responses were correlated using a
Spearman Rank Order Correlation Coefficient.Results
All subjects had a LAR. As compared to pre-allergen
baseline, the mean fall in FEV1 just before reversal
was 33.3% (range 15.1–57.7%). Salbutamol in-
creased FEV1 on average by 43% (SD: 16%) as
compared to pre-salbutamol FEV1.
At the end of the allergen challenge, the mean
eNO pre-salbutamol was 60.2 ppb (range
30.6–108.1 ppb). Salbutamol increased eNO on
average by 30% (range: 39.06–140.6 ppb; SD:17%).
The Spearman Rank Order Correlation between the
% change in FEV1 and the % change in eNO (pre-
versus post-salbutamol) was 0.51 (Po0:02) (Fig. 1).Discussion
We found a raised eNO level following reversal of
airways obstruction with inhaled salbutamol during
the LAR at 9 h post-allergen. Our data underscore
and extend earlier findings.
First, late asthmatic responses (LAR) are asso-
ciated with increased airway inflammation and
accordingly, Kharitonov and colleagues found in-
creased eNO levels 10 h post-allergen in asthmatic
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Figure 1 There was a significant correlation between the
% change in FEV1 and the % change in eNO (pre- versus
post-salbutamol); the Spearman Rank Order Correlation
was 0.51 (Po0:02).
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LAR at 9 h post-allergen.12 Second, eNO levels have
been found to relate to the airway diameter.
Various studies in asthma showed decreases in
eNO levels following bronchoconstrictor stimuli
including methacholine, histamine, hypertonic sal-
ine, adenosine monophosphate (AMP) and exercise-
induced bronchoconstriction.7,9,10 Alternatively,
following inhalation of salbutamol, Silkoff and
colleagues found increased levels of eNO corre-
sponding with increases in FEV1 in asthmatic
subjects in absence of allergen challenge.8
The present study combines all the above-
mentioned observations: in agreement with Khar-
itonov’s data,12 we found similar pre-bronchodila-
tor eNO values during the LAR at 9 h post-allergen.
And, according to the observations of Silkoff et al.8
in the absence of allergen, there was a 30% raise in
eNO levels following bronchodilation.
Our data imply that as a result of allergen-
induced bronchoconstriction, the eNO level during
the LAR is usually underestimated. Although eNO
has been shown to reflect the degree of airway
inflammation in asthma,15,16 Ricciardolo and col-
leagues have demonstrated that the allergen-
induced eNO may also act as an endogenous
bronchoprotective mechanism.17 Therefore, using
a bronchodilator following allergen challenge may
not only relieve the bronchoconstriction, but may
also support this endogenous bronchoprotective
mechanism. Another implication of our study may
be that for a correct non-invasive assessment of
airway inflammation in asthma, eNO should be
measured after (appropriate) bronchodilatation. To
enable comparison with other studies or measure-
ments in individuals, we suggest that both the
bronchodilator dose and timepoint of post-bronch-odilator eNO measurements should be standar-
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